Richard J. Turner
Plus aucun poste en cours
Historique de carrière de Richard J. Turner
Anciens postes connus de Richard J. Turner
Sociétés | Poste | Début | Fin |
---|---|---|---|
Transcriptogen Ltd.
Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Directeur/Membre du Conseil | - | 17/06/2017 |
Directeur Général | - | 17/06/2017 | |
Catalyst Venture Partners Ltd.
Catalyst Venture Partners Ltd. Investment ManagersFinance Catalyst Venture Partners Ltd. (CVP) is a London-based independent corporate finance advisory and private equity partnership established in 1999 by a group of technology entrepreneurs. Catalyst Venture Partners Ltd. | Directeur Général | 29/04/2011 | - |
Fondateur | 29/04/2011 | - | |
Private Equity Investor | 01/01/1999 | 01/09/2010 | |
Corporate Officer/Principal | 01/01/1999 | 29/04/2011 |
Statistiques
Internationale
Royaume-Uni | 3 |
Opérationnelle
Chief Executive Officer | 2 |
Founder | 1 |
Private Equity Investor | 1 |
Sectorielle
Finance | 2 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Catalyst Venture Partners Ltd.
Catalyst Venture Partners Ltd. Investment ManagersFinance Catalyst Venture Partners Ltd. (CVP) is a London-based independent corporate finance advisory and private equity partnership established in 1999 by a group of technology entrepreneurs. Catalyst Venture Partners Ltd. | Finance |
Transcriptogen Ltd.
Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Richard J. Turner
- Expérience